Immediate Impact

1 by Nobel laureates 3 from Science/Nature 78 standout
Sub-graph 1 of 21

Citing Papers

Empagliflozin in Patients with Chronic Kidney Disease
2022 Standout
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
2022 Standout
8 intermediate papers

Works of Thomas A. Golper being referenced

Drug dosing consideration in patients with acute and chronic kidney disease—a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)
2011
Continuous quality improvement: DOQI becomes K/DOQI and is updated
2001
and 4 more

Author Peers

Author Last Decade Papers Cites
Thomas A. Golper 3393 1233 1003 143 5.6k
Kai Ming Chow 2710 827 1043 182 5.1k
Salim Mujais 3697 1389 1383 120 5.7k
George R. Bailie 1992 873 500 139 4.2k
Isaac Teitelbaum 2498 823 813 102 4.0k
Judith Bernardini 3602 2027 860 94 4.8k
Ram Gokal 4209 1733 1510 189 5.6k
Joanne M. Bargman 5296 1972 1495 262 6.9k
Yong-Lim Kim 3187 846 1203 244 5.2k
Alan S. Kliger 3304 1296 721 152 5.0k
Dimitrios G. Oreopoulos 5923 1827 2158 386 8.3k

All Works

Loading papers...

Rankless by CCL
2026